乳腺癌患者血清CA15-3的临床价值

目的　评价乳腺癌患者血清CA15 3的临床价值。方法　对 42 2例良恶性乳腺疾病患者进行血清CA15 3和CEA的测定。结果　良性疾病和未转移乳腺癌患者的血清CA15 3( >30U/ml)和CEA( >15ng/ml)的阳性率较低 ,已有转移或复发的乳腺癌患者血清CA15 3的敏感性为 75 % ,CEA的敏感性为 33% ,CA15 3值升高要比临床诊断早。结论　血清CA15 3和CEA对乳腺癌的敏感性不明显。血清CA15 3和CEA的值同时持续升高或保持阳性 ,应当考虑诊断乳腺癌有转移或复发。CA15 3比其他监测指标敏感性高。

Clinical Value of Serum CA15-3 in Patients with Breast Cancer

Objective To evaluate the clinical value of CA15 3 in patients with breast cancer.Method Serum levers of CA15 3 and CEA were determined in 422 patients with benign and malignant breast diseases.Results The positive rates of CA15 3(>30U/ml) and CEA(>15ng/ml) were lower in patients with benign and without metastatic breast cancer.The sensitivity in patients with metastatic and reoccurred breast cancer was 75% in CA15 3,33% in CEA.CA15 3 increased before the clinical diagnosis.Conclusions The sensitivities of serum CA15 3 and CEA to breast cancer are not apparent.The metastasis and reoccurrence of breast cancer should be considered while serum CA15 3 and CEA increase at the same time or are persistent positive.The sensitivity of CA15 3 is higher than other indexes.